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ABSTRACT
Background: The particle distribution might differ between nebulizer therapy and metered-dose inhaler (MDI)
or dry powder inhaler (DPI) therapy because the particles repeatedly enterre-enter the airways with the nebu-
lizer. Inhaled corticosteroids (ICS) were administered with a nebulizer to assess the benefit of changes in the
distribution of particles in patients with cough variant asthma (CVA) and cough-predominant asthma (CPA).
Methods: Patients whose symptoms were not controlled by their current therapy were enrolled. In patients re-
ceiving high-dose ICS by MDI or DPI (ICS-MDIDPI), steroid therapy was switched to 1,320 μgday of nebu-
lized dexamethasone (1,600 μg as dexamethasone sodium phosphate) (chronic steroid-independent group). In
patients receiving systemic steroids regardless of their ICS-MDIDPI therapy, nebulized dexamethasone was
added and any concurrent ICS-MDIDPI therapy was halted to detect a steroid-sparing effect (chronic steroid-
dependent group). In patients with acute exacerbation of CVA or CPA and persistent symptoms despite sys-
temic corticosteroids, nebulized dexamethasone was added to assess its effect (acute group).
Results: Superior symptom control was achieved in 10 out of 12 steroid-independent patients, 3 out of 6
steroid-dependent patients, and all 7 acute patients.
Conclusions: Delivery of ICS via a nebulizer has advantages over ICS-MDIDPI in some patients with CVA
or CPA.
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INTRODUCTION
Inhaled corticosteroids (ICS) are the most effective
long-term therapy for the prevention of asthma, in-
cluding cough variant asthma (CVA) and cough pre-
dominant asthma (CPA). Deposition of inhaled aero-
sols is mediated by the processes of impaction, sedi-
mentation, diffusion, and turbulent diffusion. Particles
larger than 3 μm are mainly deposited through im-
paction, while the smaller ones are carried in the air
current due to friction and are deposited in the pe-
ripheral airways by other mechanisms.1 In the oro-
pharynx and the central bronchi, impaction is the
mechanism responsible for particle deposition.2,3 Ex-
periments involving a single inhalation in a model of
the trachea and bronchi have revealed that the depo-
sition of particles in the central airways is not uni-
form,3-7 with bifurcations being the sites of heavy
deposition.1,3,5 However, deposition of particles by a
nebulizer has never been investigated and the pattern
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of particles distribution obtained with a nebulizer is
likely to be different from that achieved with cur-
rently available devices, such as the metered-dose in-
haler (MDI) or dry powder inhaler (DPI), because
particles enter and re-enter the airways repeatedly
and fill the entire lumen during all phases of the res-
piratory cycle. There are also other differences such
as slower inspiration and humidification of the in-
spired air.
Cough receptors are distributed widely throughout
the airways from the pharynx to the bronchi8,9 and
tracheitis is known to exist in patients who have dis-
eases for which the cough is a leading symptom,10
and low particle deposition on the tracheal mucosa
might contribute to persistent cough despite ICS
therapy. We hypothesized that delivery of ICS by us-
ing nebulizer might have a different effect compared
to single-inhalation methods such as MDI or DPI due
to a change of the particle deposition pattern, espe-
cially in the central airways including the trachea.
Therefore, we employed nebulizer ICS therapy to
treat patients with CVA or CPA who had persistent
symptoms resistant to therapy including single-
inhalation ICS. The present retrospective case series
study was performed to analyze the efficacy of nebu-
lizer ICS therapy.
METHODS
The participants in this study consisted of CVA or
CPA patients whose symptoms was not adequately
controlled by their current therapy, including high-
dose ICS delivered by MDI or DPI [(ICS-MDIDPI)
800 μgday of budesonide (BUD, Pulmicort Turbu-
halerⓇ) or fluticasone propionate (FP, Flutide
DiskusⓇ)], and who were treated at the Pulmonology
Department of the International Medical Center of Ja-
pan from December 2002 to July 2006 or at the Pul-
monology Department of the National Hospital Or-
ganization Disaster Medical Center from December
2004 to July 2006. CVA was defined as continuous
cough for more than 3 weeks with no observed symp-
tomatic or audible wheezing on auscultation that re-
sponded to inhalation of β2-stimulants, based on the
simplified diagnostic criteria for CVA.11 CPA was de-
fined as chronic cough with minimal symptoms of
wheezing.12 In patients who were not being treated
with systemic steroids (chronic steroid-independent
group), ICS-MDIDPI was switched to 1,320 μg of
nebulized dexamethasone daily (1,600 μg as dex-
amathasone sodium phosphate). The doses of other
medications were not increased and no new medica-
tions were added after the initiation of nebulizer ther-
apy (the dose could be tapered or the medication
could be stopped if sufficient symptomatic improve-
ment was obtained). Patients taking systemic ster-
oids, irrespective of the dosage or use of ICS-MDI
DPI, were also enrolled in the study to observe
whether there was a steroid-sparing effect of nebu-
lizer therapy (chronic steroid-dependent group).
None of these patients had acute exacerbation and
the dose of systemic steroids was always the mini-
mum dose required to control symptoms. Any patient
who was using oral steroids for other reasons was ex-
cluded from the study. If these patients were being
treated with ICS-MDIDPI therapy, it was switched
to 1,320 μg of dexamethasone via nebulizer daily,
while patients who were not receiving ICS-MDIDPI
therapy were also given nebulized dexamethasone.
The oral steroid dose was tapered slowly if patients
showed sufficient symptomatic improvement. Nebu-
lized dexamethasone at the equivalent dose was ad-
ministered to CVACPA patients with acute exacerba-
tion due to triggering events (such as respiratory
tract infection) who had persistent cough-predom-
inant symptoms despite treatment with systemic cor-
ticosteroids (acute group). Treatment with systemic
steroids was stopped or tapered if nebulizer therapy
was effective. Immediate switching from oral predni-
solone to dexamethasone via nebulizer without con-
current use of oral treatment was also attempted un-
der careful observation. The nebulizer used in this
study was an NE-U 22 (Omron, Tokyo). This is a
mesh-type nebulizer producing an aerosol with a
mean particle diameter of 4.3-4.5 μm,13 which is simi-
lar to the particle size obtained with current jet nebu-
lizers. Each patient received 0.2 mL of dexametha-
sone sodium phosphate (DecadronⓇ, Banyu; 4 mg
mL dexamethasone sodium phosphate = 3.3 mgmL
dexamethasone) diluted in 1.8 mL of normal saline
via nebulizer twice daily. The dose was administered
in a continuous manner during inspiration and expira-
tion, and patients were instructed to expectorate any
intraoral fluid or saliva in order to reduce systemic
absorption of the steroid.
This study was approved by the ethics committee
of the International Medical Center of Japan and the
National Hospital Organization Disaster Medical Cen-
ter. Informed consent (verbal) was obtained from all
participants in the study.
RESULTS
Eighteen patients with chronic cough (including 12
steroid-independent patients and 6 steroid-dependent
patients) and 7 patients with acute exacerbation were
analyzed in this study. All patients complained of an
itchy sensation in the neck or upper anterior chest,
which improved rapidly in the patients who re-
sponded to nebulizer therapy.
CHRONIC STEROID-INDEPENDENT GROUP (Ta-
ble 1)
Of the 12 patients, 9 were receiving 800 μgday of FP
and 3 were on 800 μgday of BUD. In 10 patients
(83.3%), symptoms improved after treatment with
dexamethasone via nebulizer, including 8 who
showed a complete response and 2 with a partial re-
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Table　1　Patient characteristics and outcomes in the chronic steroid-independent group
Case
no.
Age (yr)
and sex
Type of
asthma
Dose of
ICS Rx (μg)
Other medications Side 
effects
Duration of ICS
neb Rx (Mo)before neb after neb
Complete response
 1 36M CVA BUD 800 TH, B2 0 cough 2 terminated
 2 61F CPA FP 800 TH, B2, AL TH, B2, AL GERD 3.5 terminated
 3 46M CVA FP 800 TH, B2 0 GERD 2.5 terminated
 4 26M CVA FP 800 TH, B2, AH 0 GERD 21 continued
 5 39M CVA FP 800 TH, B2, AH 0 / 3 terminated
 6 72M CVA FP 800 TH, B2 B2 / 1.5 terminated
 7 33M CVA FP 800 TH, B2, AL 0 / 10 terminated
 8 36M CPA FP 800 TH, B2 0 / 2 terminated
Partial response
 9‡ 61F CPA FP 800 TH TH edema 35 continued
10 47M CVA FP 800 TH, B2, AL TH, B2, AL / 1 terminated
No response
11 18M CVA BUD 800 TH TH / 0.5 terminated
12 57M CVA BUD 800 TH, B2 TH, B2 / 1 terminated†
ICS, inhaled corticosteroids; Rx, treatment; neb, nebulizer; CVA, cough-variant asthma; CPA, cough predominant asthma; BUD, 
budesonide; FP, fl uticasone propionate; TH, theophylline; B2, beta-2 agonist; AL, anti-leukotriene; AH, antihistamine; GERD, gastroesopha-
geal refl ux disease.
†Switched to betamethasone nebulizer (1,600 μg per day) which was effective and has been continued for 18 months.
‡In Case no.9, BUD suspension was used during ICS neb Rx.
sponse. Complete response was defined as the total
disappearance of symptoms despite stopping nebu-
lizer therapy or the almost complete resolution of
symptoms with continuing nebulizer therapy. Partial
response was defined as an obvious reduction of
symptoms but some residual disturbance of daily ac-
tivities. Seven patients showed a complete response
and their nebulizer therapy was stopped (cases 1-3
and 5-8). In one patient with a partial response, cough
showed rapid improvement after delivery of dex-
amethasone via the nebulizer. The patient then
switched to inhalation of a BUD suspension (500 μg
twice daily), which was imported by the patient from
overseas for personal use, resulting in further im-
provement (case 9). This patient had edema of the
face and extremities after receiving dexamethasone
via the nebulizer, which improved after starting the
inhaled BUD suspension. Treatment with BUD was
continued for 3 months, and the daily dose of BUD
was reduced to 250 μg twice daily during the latter
half of this period without any reduction of efficacy.
Subsequently, nebulized dexamethasone was reintro-
duced, resulting in slight worsening of the patient’s
cough and recurrence of edema.
In 2 patients in whom nebulized dexamethasone
was effective (cases 4 and 7), treatment was switched
from dexamethasone to betamethasone via nebulizer
at a dose of 1,600 μg per day, resulting in further im-
provement of symptoms. In case 12, nebulized dex-
amethasone was not effective, but the same dose of
nebulized betamethasone was effective and has been
continued for 18 months.
CHRONIC STEROID-DEPENDENT GROUP (Table
2)
Of the 6 patients in this group, 2 were not using ICS,
while 4 were on high doses of ICS-MDIDPI. In 3 pa-
tients, nebulized dexamethasone was effective, in-
cluding 2 complete responses and 1 partial response.
A complete response was defined as a permanent re-
duction of oral steroid use, while a partial response
was defined as a temporary reduction. In a patient
with Churg-Strauss syndrome who had suffered from
steroid-dependent asthma for 6 years (case 1), intro-
duction of nebulized dexamethasone was followed by
reduction of the dose of betamethasone from 0.75 mg
to 0.25 mg daily and cessation of treatment with clen-
buterol and montelukast. Respiratory symptoms re-
solved on the second day of nebulizer therapy and
acute exacerbation (related to coughing fits) did not
occur thereafter. Nebulized dexamethasone was
ceased after 18 months due to good control of symp-
toms, but low-dose betamethasone was continued be-
cause of prior long-term administration. In case 2,
symptoms improved rapidly and oral prednisolone
was ceased within 2 weeks. Nebulizer therapy was
also ceased after 2 months. Case 3 showed a partial
response. Although a steroid-sparing effect was ob-
served when the patient was taking 5 mgday of pred-
nisolone, symptomatic relief was temporary and fluc-
tuating, so treatment was switched back to 800 μg of
DPI-BUD daily after 12 months.
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Table　2　Patient characteristics and outcomes in the chronic steroid-dependent group
Case no. Age (yr)and sex
Type of
asthma
Duration of steroid
dependency (yr)
Dose of
ICS Rx (μg)
Oral steroid dose (mg)
Side effects Duration of ICSnebulizer Rx (Mo)before neb after neb
Complete response
1 61M CPA  6 BUD 800 BMS 0.75 BMS 0.25 / 18 terminated
2 75M CPA  0.1 / PSL 5 PSL 0 hoarseness  2 terminated
Partial response
3 73F CPA  1 BUD 800 PSL 12.5 PSL7.5 / 12 terminated
No response
4 66M CPA 11 FP 800 PSL 5 PSL 5 /  3 terminated
5 42M CPA  7 / BMS 0.5/1.0 BMS 0.5 /  8 terminated
6 72F CPA  1.5 FP 800 PSL 7.5 PSL 7.5 /  1 terminated
ICS, inhaled corticosteroids; Rx, treatment; neb, nebulizer; CPA, cough predominant asthma; BUD, budesonide; FP, fl uticasone propio-
nate; BMS, betamethasone; PSL, prednisolone.
Table　3　Patient characteristics and outcomes in the acute group
Case
no.
Age (yr)
and sex
Type of
asthma
Systemic steroid
dose (mg)
Duration of steroid use (d)
Side effects Duration of ICSneb Rx (Mo)before neb after neb
Complete response
1 26F CVA PSL20  3 2 / 0.5 terminated
2 66M CPA PSL30 10 4 / 2 terminated
3 36F CPA PSL30  6 0† / 1 terminated
4 42F CPA PSL30  5 0† / 1 terminated
5 32F CPA PSL20  7 0† / 3 terminated
Partial response
6 68F CVA PSL20 11 0† GERD, fatigue, appetite loss 1 terminated
7 61F CVA PSL20  7 0† / 2.5 terminated
neb, nebulizer; ICS, inhaled corticosteroids; Rx, treatment; CVA, cough-variant asthma; CPA, cough predominant asthma; PSL, predniso-
lone; GERD, gastroesophageal refl ux disease.
†In these patients, systemic steroids were stopped and switched to ICS via nebulizer, because of complete lack of improvement of cough 
by oral PSL.
ACUTE GROUP (Table 3)
All 7 patients showed improvement after introduction
of nebulized dexamethasone, including 5 patients
with a complete response and 2 with a partial re-
sponse. A complete response was defined as the reso-
lution of symptoms along with cessation of systemic
steroid therapy. A partial response was defined as ob-
vious improvement of symptoms without resolution.
Despite receiving oral steroid therapy for 3-11 days
before starting nebulized dexamethasone, all patients
had intractable cough, causing sleep disturbance and
exhaustion. In 5 patients (cases 3-7), administration
of systemic steroids was stopped and treatment was
switched to nebulizer therapy because of the com-
plete lack of improvement of cough by oral predniso-
lone. Among the 5 complete responders, nebulizer
therapy was stopped in 3 patients (cases 1-3) after
complete resolution of symptoms. The other two pa-
tients (cases 4 and 5) were switched back to DPI
therapy after obtaining good control of symptoms.
Among the 2 partial responders, nebulizer therapy
was stopped in case 6 due to side effects. In case 7,
symptoms showed marked improvement, but nebu-
lizer therapy was ceased after 2.5 months at the pa-
tient’s request.
ADVERSE EVENTS
Nine adverse events occurred in 7 patients (28.0%),
including 4 cases of heartburn, and 1 case each of
hoarseness, edema, anorexia with upper abdominal
pain, fatigability, and cough. Heartburn improved af-
ter stopping dexamethasone nebulizer therapy in 3
patients, while it was controlled with an H2-blocker
and nebulizer therapy was continued in 1 patient.
Two of these patients had a history of gastroe-
sophageal reflux disease. The patient with cough in-
itially showed rapid improvement after starting nebu-
lizer therapy, but then developed paradoxical
nebulizer-induced mild cough. After nebulizer ther-
apy was ceased, the patient had no further symptoms.
Nebulized Corticosteroid for Tracheitis
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DISCUSSION
The present findings demonstrate that there may be
a subpopulation of patients with CVA or CPA inade-
quately controlled by high dose ICS-MDIDPI ther-
apy who respond to nebulized ICS. Nebulized ICS
has been employed to treat infants14 and the elderly15
who cannot properly use inhalation devices. Some
studies have also shown the efficacy of this treatment
for severe adult asthma. Previous studies have indi-
cated that an oral steroid-sparing effect for typical
asthma is seen in patients using 4,000 μg16 or 4,000 to
8,000 μg of BUD inhaled suspension daily,17 or else
1,000 to 4,000 μg on nebulized FP daily (with the
strongest effect in the 4,000 μg group).18 For acute
exacerbation, 12,00019 to 20,000 μg per day20 of BUD
inhaled suspension has been tried to control symp-
toms. The efficacy of particle deposition by nebulizers
is not high, and single-dose studies using β2-agonists
have suggested that a dose 4 to 8 times higher than
the target dose is required in order to achieve equipo-
tency between nebulizer therapy and MDI therapy
with a spacer.21-23 The lung deposition rate of BUD in-
haled suspension is approximately 14%-16%24 when a
nebulizer is used with a breath synchronizer, which
only allows generation of mist during inspiration to
maximize the amount of drug inhaled by minimizing
drug loss during expiration. Therefore, there would
be less particle deposition throughout the airways
when 1,000 μg of the drug was given via nebulizer
without a breath synchronizer in one of our chronic
steroid-independent patients (case 9) compared with
a deposition rate of 32% during treatment with 800 μg
of BUD via turbuhaler.25 Thus, the symptoms of our
patient were more effectively suppressed by deposi-
tion of fewer BUD particles via nebulizer than by
deposition of more particles with DPI. Also, at least in
case 9, it was suggested that 1,320 μg of nebulized
dexamethasone daily is less potent than 1,000 μg of
BUD inhaled suspension, and this result is supported
by the report that the topical anti-inflammatory po-
tency of dexamethasone is about 19 of that of BUD
based on their relative binding affinities for the rat
glucocorticoid receptor.26
The better clinical outcome obtained with nebu-
lized ICS, despite deposition of fewer particles
throughout the airways than with DPI, suggests that
a change in the distribution of corticosteroid particles
in the central airway was achieved by nebulizer ther-
apy. The single inhalation experiment in the tra-
cheobronchial model revealed that the distribution of
particles is not uniform in the central airway.3-7 Bifur-
cations in the proximal tracheobronchial tree are the
main sites of deposition because the particles have
considerable inertia so that their trajectory deviates
from fluid streamlines.3,5 The region immediately dis-
tal to the larynx is another site of enhanced particle
deposition because of the laryngeal jet.3 A study of
aerosol behavior using laser Doppler velocimetry and
a fluorescent dye revealed marked deposition within
the first 3-4 cm of the trachea.6 Another study of intra-
bronchial and intratracheal deposition using a hollow
cast of a human larynx plus tracheobronchial tree
showed that there is a deposition ‘hot-spot’ in the tra-
chea located 2 cm below the larynx and that deposi-
tion is also enhanced at the tracheal bifurcation due
to changes of air flow at this region.4 Most of the
deposition of particles in the trachea occurs within 2
cm distal to the larynx, accounting for 60% of total in-
tratracheal deposition. This pattern of deposition was
reported to be independent of flow rate (at 15-60 l
min) and particle size (>2 μm),4 while total intra-
tracheal deposition increases with the flow rate.6
Then deposition decreases in the next part of the tra-
chea and is uniform for about 6 cm, after which depo-
sition increases gradually as the trachea attains its
transitional elliptical shape prior to dividing into the
main bronchi. In both the trachea and the main bron-
chi, the distribution of air flow and turbulence is not
uniform,7 and enhanced accumulation of particles on
the inner sides of the main bronchi is common.27 On
the other hand, the main sites of particle deposition
on expiration are the lumens of the parent branches
above the bifurcations.28,29 This means that the lower
part of the trachea, where there is little deposition of
particles during inspiration, is covered during expira-
tion provided that there are enough particles remain-
ing in the airway at the time of the expiratory phase.
Current devices for delivery of ICS, such as the MDI
or the DPI, require the total dose to be inhaled at
once. As a result, the distribution of the inhaled parti-
cles might be far from uniform (as shown by previous
single-inhalation experiments), with few particles in
the central airways at the end-inspiratory phase and
limited deposition on the mucosa of the trachea in the
expiratory phase. To date, the distribution of particles
deposited by nebulizer therapy has never been re-
ported (personal communication). With nebulizer
therapy, the central airways are filled with particles
even during the end-inspiratory phase and the chance
of deposition on the mucosa during the expiratory
phase may be increased, suggesting that nebulizer
therapy may achieve a more uniform distribution of
the particles within the trachea.
Airway sensory receptors, such as rapidly adapting
airway mechanoreceptors (RARs) and C-fiber end-
ings, are not only distributed in the bronchi but are
also found in the trachea and the larynx,8 and en-
hanced afferent excitability of these receptors is asso-
ciated with inflammation.9 Tracheitis is commonly as-
sociated with diseases that cause cough, and an itchy
sensation in the neck and upper anterior chest indi-
cates inflammation of the trachea.10 In our experi-
ence, rapid disappearance of such an itchy sensation
in the upper anterior chest and neck after nebulizer
ICS therapy was observed in patients who responded
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to this therapy. These findings suggest that the tra-
chea might have been treated more effectively by
nebulizer therapy due to a change in the distribution
of drug particles. It is possible that the patients with
CVA or CPA who failed to respond or responded par-
tially to ICS-MDIDPI in this study might have had
residual tracheal inflammation whereas their bron-
chial inflammation was controlled. This suggests that
the efficacy of ICS therapy should not only be as-
sessed from lung deposition of drug particles but also
from tracheal deposition in patients with intractable
asthmatic cough.
The increased benefit of nebulized dexamethasone
could also be a result of greater systemic absorption30
than after treatment with DPI-FP or DPI-BUD. How-
ever, this could not completely explain the improve-
ment noted because our study showed that nebulized
dexamethasone was more beneficial for acute exacer-
bation of CVA and CPA than administration of oral
corticosteroids. Also, the reduction of the oral steroid
dose in the steroid-dependent group was greater than
the amount absorbed (a decrease of 0.5 mgday of
betamethasone in case 1 or 5 mgday of prednisolone
in cases 2 and 3). The other possibility is that a more
homogenous distribution of drug particles in the pe-
ripheral airways can be achieved by nebulizer ther-
apy, which leads to better control of cough. The
mechanism of cough in CVA has been suggested to
involve bronchospasm,31 similar to that in typical
asthma, because infiltration of eosinophils,32 thicken-
ing of the subepithelial layer in subsegmental bron-
chi,33 and an increase of eosinophils in BAL fluid32
have also been reported in CVA and these patients re-
spond to bronchodilator therapy. On the other hand,
O’Connel et al. hypothesized that CVA patients had
inflammation limited to the large airways,34 which is
where cough receptors are most abundant.8 Rapid
disappearance of an itchy sensation in the upper ante-
rior chest and throat of our patients suggests that the
mechanism of cough involves more than just the pe-
ripheral airways.
In general, systemic corticosteroid therapy is effec-
tive for acute exacerbation of CVA as well as for typi-
cal asthma, but a few patients are refractory to such
therapy, as seen in our acute group. We found rapid
improvement only after using nebulized dexametha-
sone to treat such refractory patients with acute exac-
erbation of CVA or CPA, regardless of whether it was
combined with oral steroids or they were switched to
nebulizer therapy alone. This suggests that the im-
provement of symptoms was not only related to sys-
temic effects of corticosteroid therapy. The exact
mechanism involved is unknown, but it is possible
that steroid levels in the trachea were low with sys-
temic therapy in our patients, making nebulized ICS a
possible alternative medication for tracheitis-related
exacerbation of CPACVA.
During follow-up, the effect of nebulized ICS did
not always persist. Administration of a dose of 1,320
μg of dexamethasone via nebulizer is sufficient to
treat the trachea, but this treatment is less potent
than 800 μg of inhaled FP or 800 μg of inhaled BUD,
so the anti-inflammatory effect on the entire airway
tree may be weaker. Therefore, treatment with nebu-
lized dexamethasone should be accompanied with or
switched to ICS-MDIDPI, depending on the clinical
course of the patient. Furthermore, gastroesophageal
reflux is a side effect of nebulized dexamethasone
that might contribute to the recurrence of cough. An-
other possibility is that additives such as sulfites in
the dexamethasone solution could act as irritants dur-
ing long-term treatment.15 The higher rate of adverse
effects with dexamethasone nebulizer therapy com-
pared to ICS-MDIDPI therapy suggests that the
safety of this method for long-term management of
CVA or CPA is uncertain. On the other hand, long-
term inhalation of BUD suspension has been clini-
cally proven to be safe.35,36 This drug was not avail-
able in Japan when the present study was conducted,
so its clinical benefit for the treatment of intractable
CVA and CPA should be further evaluated in future
studies.
In summary, nebulized ICS was more effective
than DPI in certain patients with CVA or CPA. A
change in the distribution of drug particles delivered
via a nebulizer with increased deposition in the tra-
chea is thought to be the main mechanism leading to
improvement. Patients with CVA or CPA who fail to
respond or only respond partially to ICS-MDIDPI
therapy might have residual inflammation in the tra-
chea although their bronchial inflammation is con-
trolled. Tracheitis should be considered separately
from bronchitis to achieve better awareness of the ex-
istence of a subgroup of CVA and CPA patients who
can benefit from nebulized ICS.
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